It passed the House of Representatives but awaited action in the Senate. In 2022, Congress attempted to expand this cap to all insured patients with the Build Back Better bill. Patients who are covered under the Medicare Part D plan also now have a $35 out-of-pocket monthly cap for their insulin. government is taking action to make this life-saving medication more accessible. Large insulin manufacturers Sanofi and Eli Lilly announced earlier this year that in late 2023 and early 2024 they would begin capping out-of-pocket costs at $35 per month for their most common insulin products. Retail prices for insulins like Afrezza, Xultophy, and Soliqua continue to rise.īut while retail prices for insulin have climbed 32% since 2014, relief may be coming in the near future. Not all insulins saw price drops, though. An insulin medication that has a concentration of U-100 has 100 insulin units per milliliter. Then, from January 2020 to July 2023, it dropped by 10.6%, from about $0.32 to $0.29.Īn insulin unit is the most basic measure of insulin used for dosing.
Over 9 million Americans rely on insulin, and they have been raising red flags over soaring prices for years.įrom January 2014 to April 2019, the average cash price per insulin unit rose 54%, from $0.22 to $0.34.
